Kepley BioSystems Incorporated (KBI) is a North Carolina biotech founded in 2013. Focused on disruptive innovations and global solutions, KBI is poised to compete in multi-billion dollar markets with answers to urgent social and environmental challenges, including:
- Sustainable, synthetic crustacean and fish bait;
- On-site, terrestrial production of aquaculture feed;
- Enriched feed for migrating shorebirds;
- Ranching horseshoe crabs to sustainably harvest LAL (limulus amebocyte lysate), vital to ensuring global safety of pharmaceutical and medical devices;
- A canine excretion aid designed as the "solution for the dawdling dog";
- Bringing laboratory quality to bedside testing;
- …and an autologous breast cancer treatment as an alternative to chemotherapy.
KBI would welcome an array of investment possibilities, including: equity for commercialization/scale-up; single-project divestiture; and/or full acquisition of KBI as a dynamic resource to accelerate corporate innovation.
KBI originated at the Joint School of Nanoscience and Nanoengineering (JSNN), North Carolina A&T State University and The University of North Carolina at Greensboro.
Now located at the Gateway University Research Park with collaborative access to the resources of JSNN, the KBI leadership team includes Professor Christopher Kepley and Dr. Anthony Dellinger, working with lead inventor Terry E. Brady, located on the Caribbean island of Anguilla in the British West Indies.
For more information, please contact us below: